Online citations, reference lists, and bibliographies.
← Back to Search

Dirlotapide: A Review Of Its Properties And Role In The Management Of Obesity In Dogs.

J. Wren, J. Gossellin, S. Sunderland
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Dirlotapide is a microsomal triglyceride transfer protein (MTP) inhibitor developed specifically for canine weight reduction. MTP catalyzes the assembly of triglyceride-rich apolipoprotein-B containing lipoproteins to form chylomicrons in the intestinal mucosa and very low-density lipoproteins in the liver. Following oral administration, dirlotapide has in vivo selectivity for intestinal MTP compared with hepatic MTP. In addition to reducing intestinal fat absorption, dirlotapide also reduces food intake in a dose-dependent manner, probably via increased release of peptide YY into the circulation. The decrease in food intake is responsible for the majority of the weight reduction effect. In clinical use, it is recommended to adjust the dose according to the observed weight loss of each individual. The initial dose of 0.05 mg/kg is doubled after 14 days and then adjusted monthly, the maximum permitted daily dose is 1.0 mg/kg, although doses as high as 10 mg/kg have been administered to dogs without severe adverse experience in safety studies. Dirlotapide can be used without necessitating changes to the current feeding or exercise regimens, but it is desirable to monitor the food intake during weight-stabilization to establish revised feeding and exercise routines that will minimize the risk of weight regain post-treatment. The drug offers a novel approach that is applicable in cases where dietary management alone has proved to be unsuccessful.
This paper references
10.1002/HEP.1840040621
Morphologic Features of the Liver in Abetalipoproteinemia
M. I. Avigan (1984)
10.1111/J.1748-5827.1991.TB00930.X
Occurrence and management of obesity in companion animals
S. W. Crane (1991)
10.1097/00041433-199404000-00003
The molecular basis of abetalipoproteinemia.
R. Gregg (1994)
10.1016/0271-5317(95)00063-O
The effect of weight loss regimen on subsequent weight maintenance in dogs
D. Laflamme (1995)
10.5326/15473317-33-3-253
Evaluation of weight loss protocols for dogs.
D. P. Laflamme (1997)
Foods and techniques for managing obesity in companion animals.
W. J. Burkholder (1998)
10.1146/ANNUREV.NUTR.20.1.663
The role of the microsomal triglygeride transfer protein in abetalipoproteinemia.
N. Berriot-Varoqueaux (2000)
10.2460/JAVMA.2000.216.1089
Effect of weight reduction on clinical signs of lameness in dogs with hip osteoarthritis.
J. Impellizeri (2000)
10.1021/JM010294E
Diaminoindanes as microsomal triglyceride transfer protein inhibitors.
G. Ksander (2001)
10.2460/JAVMA.2002.220.1315
Effects of diet restriction on life span and age-related changes in dogs.
R. D. Kealy (2002)
10.1016/S0014-2999(02)01422-X
Orlistat: its current status as an anti-obesity drug.
A. Ballinger (2002)
Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms.
G. Chang (2002)
10.1517/13543776.13.4.479
Novel microsomal triglyceride transfer protein inhibitors
S. J. Williams (2003)
10.1194/JLR.M300094-JLR200
CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans.
C. E. Chandler (2003)
10.1152/AJPGI.00278.2003
Slowing intestinal transit by PYY depends on serotonergic and opioid pathways.
H. Lin (2004)
10.1210/EN.2004-0089
Minireview: Gut peptides regulating satiety.
M. Druce (2004)
10.1152/AJPGI.00536.2003
Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide.
S. Stanley (2004)
10.1248/BPB.28.247
Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation.
K. Ueshima (2005)
10.1111/J.1365-2885.2007.00865.X
Absorption, distribution, metabolism, and excretion of dirlotapide in the dog.
D. Merritt (2007)
10.1111/J.1365-2885.2007.00867.X
Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America.
J. Wren (2007)
10.1111/J.1365-2885.2007.00854.X
The safety of dirlotapide in dogs.
J. Wren (2007)
10.1111/J.1365-2885.2007.00866.X
An evaluation of dirlotapide to reduce body weight of client-owned dogs in two placebo-controlled clinical studies in Europe.
J. Gossellin (2007)
10.1111/J.1365-2885.2007.00856.X
Influence of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on the digestibility of a dry expanded diet in adult dogs.
C. Kirk (2007)
10.1111/J.1365-2885.2007.00855.X
Evaluation of dirlotapide for sustained weight loss in overweight Labrador retrievers.
J. Gossellin (2007)
10.1111/J.1365-2885.2007.00862.X
Pharmacokinetics of dirlotapide in the dog.
D. Merritt (2007)
10.1111/J.1365-2885.2007.00853.X
Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs.
J. Wren (2007)



This paper is referenced by
10.1021/acs.jmedchem.0c01502
A Structural Analysis of the FDA Green Book-Approved Veterinary Drugs and Roles in Human Medicine.
Kevin A. Scott (2020)
10.1016/j.prevetmed.2018.08.016
How effective are interventions designed to help owners to change their behaviour so as to manage the weight of their companion dogs? A systematic review and meta-analysis.
M. Krasuska (2018)
10.1016/j.cvsm.2017.02.007
Conservative Management of Hip Dysplasia.
T. Harper (2017)
10.1007/164_2016_46
Gut Hormone Regulation and Secretion via FFA1 and FFA4.
F. Gribble (2017)
Effect of a Leucine/Pyridoxine Nutraceutical on Energy Metabolism and Satiety in Lean and Obese Dogs
M. Murphy (2014)
10.2217/clp.13.1
The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol
D. Blom (2013)
10.1007/978-1-4614-4439-8_16
Human: Veterinary Technology Cross Over
A. Baird (2013)
10.1194/jlr.M029041
Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying
G. Ables (2012)
Intestinal DGAT 1 defi ciency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying Gene
P. Ables (2012)
10.1124/jpet.110.173807
Pharmacological Characterization of Diethyl-2-({3-dimethylcarbamoyl-4-[(4′-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein
Y. Mera (2011)
10.1111/J.2044-3862.2011.00097.X
The difficult diabetic: Part 2
A. Cook (2011)
10.1124/jpet.110.177527
A Small-Molecule Inhibitor of Enterocytic Microsomal Triglyceride Transfer Protein, SLx-4090: Biochemical, Pharmacodynamic, Pharmacokinetic, and Safety Profile
Enoch Kim (2011)
10.19052/MV.575
Manejo farmacológico de la hiperlipidemia en caninos
A. Carrillo (2011)
10.1124/jpet.110.176560
JTT-130, a Novel Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein, Suppresses Food Intake and Gastric Emptying with the Elevation of Plasma Peptide YY and Glucagon-Like Peptide-1 in a Dietary Fat-Dependent Manner
T. Hata (2011)
10.1152/ajpregu.00610.2010
Dietary fat sensing via fatty acid oxidation in enterocytes: possible role in the control of eating.
W. Langhans (2011)
10.1111/j.1440-1681.2011.05513.x
Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats
V. Dhote (2011)
10.1016/j.bmcl.2011.05.099
Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide.
R. Robinson (2011)
10.1007/978-3-642-10324-7
Comparative and veterinary pharmacology
F. Cunningham (2010)
10.1007/978-3-642-10324-7_8
New technologies for application to veterinary therapeutics.
J. Riviere (2010)
10.1016/j.cvsm.2009.10.009
Obesity in dogs and cats: a metabolic and endocrine disorder.
D. Zoran (2010)
10.1152/ajpendo.90949.2008
Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism.
Y. Shi (2009)
10.1007/s11259-009-9232-5
Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles
B. Dobenecker (2009)
ii THE COMPARISON OF THE EFFECT OF DIETARY CHANGES OR DIRLOTAPIDE TREATMENT ON CANINE OBESITY IN A SMALL ANIMAL VETERINARY PRACTICE A Report of a Senior Study
A. McRee (2009)
10.1016/j.bmcl.2009.01.044
Discovery of benzothiazole derivatives as efficacious and enterocyte-specific MTP inhibitors.
C. Vu (2009)
10.2460/javma.233.5.717
An evidence-based review of the use of therapeutic foods, owner education, exercise, and drugs for the management of obese and overweight pets.
P. Roudebush (2008)
10.1055/S-0038-1622691
Neue Arzneimittel für Kleintiere 2007
I. Emmerich (2008)
10.1016/j.jfms.2008.02.004
Changes in body composition during weight loss in obese client-owned cats: Loss of lean tissue mass correlates with overall percentage of weight lost
A. German (2008)
10.1124/dmd.108.021196
In Vitro Drug-Drug Interaction Screens for Canine Veterinary Medicines: Evaluation of Cytochrome P450 Reversible Inhibition
Divesh Aidasani (2008)
10.1111/J.1365-2885.2007.00865.X
Absorption, distribution, metabolism, and excretion of dirlotapide in the dog.
D. Merritt (2007)
10.1111/J.1365-2885.2007.00867.X
Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America.
J. Wren (2007)
10.1111/J.1365-2885.2007.00854.X
The safety of dirlotapide in dogs.
J. Wren (2007)
10.1111/J.1365-2885.2007.00866.X
An evaluation of dirlotapide to reduce body weight of client-owned dogs in two placebo-controlled clinical studies in Europe.
J. Gossellin (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar